کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2101413 1546259 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies
ترجمه فارسی عنوان
سیکلوفسفامید پس از پیوند تک پروتئین پس از پروفیلاکسی بیماری پس از پیوند با آنتی ژن لنفوسیت های انسانی مرتبط با پیوند مغز استخوان مرتبط با آن در بیماران مبتلا به بدخیم هماتولوژیک
کلمات کلیدی
سیکلوفسفامید، پیوند مغز استخوان کودکان، پیشگیری از بیماری پروستات در مقابل میزبان، بدخیمی های هماتولوژیک
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


• Single-agent post-transplantation cyclophosphamide provided effective graft-versus-host disease prophylaxis for pediatric human leukocyte antigen–matched bone marrow transplantation.
• No differences in overall survival or event-free survival between post-transplantation cyclophosphamide and calcineurin inhibitor–based graft-versus-host disease prophylaxis were observed.
• Improved 1-year post–bone marrow transplantation renal function after post-transplantation cyclophosphamide was observed.
• Early cessation of immunosuppression provides a platform for post–bone marrow transplantation immunotherapy.

High-dose cyclophosphamide given after HLA-matched related and unrelated allogeneic bone marrow transplantation (BMT) for patients with hematologic malignancies is effective single-agent graft-versus-host disease (GVHD) prophylaxis in adults. Data describing outcomes for pediatric and young adult patients have not been reported. Between the years 2007 and 2013, 29 pediatric and young adult patients ages ≤21 years of age treated at our institution for high-risk hematologic malignancies underwent myeloablative HLA-matched related T cell–replete BMT. Eleven patients received post-transplantation cyclophosphamide (PTCy) as single-agent GVHD prophylaxis and were followed prospectively. Eighteen patients received calcineurin inhibitor (CNI)–based standard GVHD prophylaxis and were studied retrospectively as a control group. No acute GVHD (aGVHD) developed in patients receiving PTCy, whereas patients receiving CNI-based GVHD prophylaxis had cumulative incidences of grades II to IV and grades III and IV aGVHD of 27% and 5%, respectively. No patients receiving PTCy developed chronic GHVD, compared to 1 in the control group. Two-year overall survival was similar between the 2 groups (54% PTCy versus 58% CNI-based prophylaxis), as was event-free survival (42% PTCy versus 47% CNI-based). The 5-year cumulative incidence of relapse was 58% for PTCy and 42% for CNI-based GVHD prophylaxis (P = .45). These results suggest that PTCy is a safe and efficacious method of GVHD prophylaxis after an HLA-matched related BMT in the pediatric and young adult population that affords patients to be off all post-transplantation immunosuppression on day +5.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: - Volume 22, Issue 1, January 2016, Pages 112–118
نویسندگان
, , , , , , , , , , , ,